HIV-1-infected patients with advanced disease failing a raltegravir-containing salvage regimen in São Paulo, Brazil

International Journal of Antimicrobial Agents

Volumn 43, Issue 3, 2014, Pages 287-291

  De Souza Cavalcanti, Jaqueline ^a   De Paula Ferreira, Joao Leandro ^a   Vidal, Jose Ernesto ^b   De Souza Guimarães, Paula Morena ^a   Moreira, Denise Helena ^a   De Macedo Brigido, Luis Fernando ^a  

^a INSTITUTO ADOLFO LUTZ   (Brazil)

^b INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

Author keywords

Brazil; Genotype; HIV 1; Integrase; Raltegravir; Resistance

Indexed keywords

ALANINE; ARGININE; ASPARAGINE; CYSTEINE; DARUNAVIR PLUS RITONAVIR; ELVITEGRAVIR; ENFUVIRTIDE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HISTIDINE; LAMIVUDINE; LYSINE; MARAVIROC; RALTEGRAVIR; SERINE; TENOFOVIR; TYROSINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BRAZIL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT DURATION; VIREMIA; VIRUS LOAD;

BRAZIL; GENOTYPE; HIV-1; INTEGRASE; RALTEGRAVIR; RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PREVALENCE; PYRROLIDINONES; SALVAGE THERAPY; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; YOUNG ADULT;

EID: 84896490811     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.10.020     Document Type: Article

References (15)

1. R.T. Steigbigel, D.A. Cooper, P.N. Kumar, J.E. Eron, M. Schechter, M. Markowitz BENCHMRK Study Teams Raltegravir with optimized background therapy for resistant HIV-1 infection N Engl J Med 359 2008 339 354
2. J.L. Lennox, E. DeJesus, A. Lazzarin, R.B. Pollard, J.V. Madruga, D.S. Berger STARTMRK Investigators Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 374 2009 796 806
3. P.E. Sax, E. DeJesus, A. Mills, A. Zolopa, C. Cohen, D. Wohl GS-US-236-0102 Study Team Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks Lancet 379 2012 2439 2448
4. M. Kobayashi, T. Yoshinaga, T. Seki, C. Wakasa-Morimoto, K.W. Brown, and R. Ferris et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor Antimicrob Agents Chemother 55 2011 813 821
5. A.S. Espeseth, P. Felock, A. Wolfe, M. Witmer, J. Grobler, and N. Anthony et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase Proc Natl Acad Sci U S A 97 2000 11244 11249
6. J.L. Mbisa, S.A. Martin, and P.A. Cane Patterns of resistance development with integrase inhibitors in HIV Infect Drug Resist 4 2011 65 76
7. V.A. Johnson, V. Calvez, H.F. Günthard, R. Paredes, D. Pillay, and R.W. Shafer et al. Update of the drug resistance mutations in HIV-1: March 2013 Top Antivir Med 21 2013 6 14 [Erratum in: Top Antivir Med 2013;21:46]
8. M. Kobayashi, K. Nakahara, T. Seki, S. Miki, S. Kawauchi, and A. Suyama et al. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants Antiviral Res 80 2008 213 222
9. J. Souza Cavalcanti, A. Minhoto Lança, J.L. de Paula Ferreira, M. da Eira, D.S. de Souza Dantas, and L.F. de Macedo Brígido In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen Antiviral Res 95 2012 9 11
10. J.E. Vidal, A.T. Song, M.L. Matos, D. Bartmann, G.D. Anjos, and É.D. Miranda et al. High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil Braz J Infect Dis 17 2013 41 47
11. K. Van Laethem, Y. Schrooten, K. Covens, N. Dekeersmaeker, P. De Munter, and E. Van Wijngaerden et al. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes J Virol Methods 153 2008 176 181
12. R. Rodrigues, C.M.P. Vazquez, J.K. Colares, R.M. Custodio, F. Bonásser Filho, and L.R. Souza et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 infected patients enrolled in genotype testing at the Central Public Health Laboratory, São Paulo, Brazil: preliminary results Mem Inst Oswaldo Cruz 100 2005 97 102
13. C.P. Passaes, M.L. Guimarães, S.W. Cardoso, J.H. Pilotto, V. Veloso, and B. Grinsztejn et al. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study J Med Virol 84 2012 1869 1875
14. A.G. Marcelin, C. Delaugerre, C. Beaudoux, D. Descamps, L. Morand-Joubert, C. Amiel ANRS AC11 Resistance Group A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure Int J Antimicrob Agents 42 2013 42 47
15. S. Gallien, C. Delaugerre, I. Charreau, J. Braun, T. Boulet, and A. Barrail-Tran et al. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia AIDS 25 2011 665 669